LGLionel Ginsberg

Lionel Ginsberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lionel Ginsberg has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Göteson

    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg , Gothenburg 431 41

    1 shared publication
  • David Moreno-Martínez

    Lysosomal Storage Disorders Unit Royal Free Hospital NHS Foundation Trust and University College London London UK

    1 shared publication
  • Derralynn A. Hughes

    Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London

    1 shared publication
  • Guillem Pintos-Morell

    Clinical Biochemistry Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Barcelona 08035, Spain

    1 shared publication
  • Henrik Zetterberg

    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg , Gothenburg 431 41

    1 shared publication
  • Jan-Willem Taanman

    Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology , London NW3 2PF

    1 shared publication

Latest Publications

  • Open Access

    Plasmalogen deficiency and the Alzheimer’s disease risk of apolipoprotein E4

    by Jenny Hällqvist, Jan-Willem Taanman, Andreas Göteson, Wendy E Heywood, Jonathan M Schott, John Hardy, Mikael Landén, Henrik Zetterberg, Kevin Mills, Lionel Ginsberg

    The ε4 allele of the APOE gene, encoding the E4 isoform of apolipoprotein E, is the leading genetic risk factor for late-onset Alzheimer’s disease. While many potential mechanisms have been proposed to explain this risk, no dominant or unifying process has yet emerged. Here, we explore the primary function of apolipoprotein E in lipid transport and metabolism, by examining its lipid association properties, to establish whether they show isoform dependence and thereby could mediate Alzheimer’s risk. We focus on ethanolamine plasmalogen, a phospholipid subclass known to be depleted in Alzheimer’s disease brain. We purified apolipoprotein E from human cerebrospinal fluid by immunoprecipitation using an anti-pan-apolipoprotein E monoclonal antibody bound to magnetic beads, then conducted lipidomic and proteomic analyses of the precipitates by mass spectrometry. The cerebrospinal fluid samples were obtained from cognitively intact, relatively young individuals with no evidence of amyloid pathology and with known apolipoprotein E isoform status (E3E3, n = 5; E3E4, n = 4; E4E4, n = 5). The molar ratio of ethanolamine plasmalogen to apolipoprotein E was 29.5% lower for E4E4 than for E3E3 (P = 0.007) with a biological gradient: E3E3 > E3E4 > E4E4 (P = 0.03). No similar trends and differences were found for phosphatidyl ethanolamine, a chemically related lipid (P = 0.5). Compared to E3E3, the molar ratio of ethanolamine plasmalogen to phosphatidyl ethanolamine was significantly reduced for E3E4 (P = 0.0016) and E4E4 (P = 0.0001). The latter deficiency was similar in magnitude to that found in Alzheimer’s disease brain relative to control. The finding that ethanolamine plasmalogen is depleted in apolipoprotein E4 relative to E3 strengthens the view that brain deficiency of this same lipid contributes to Alzheimer’s disease causation, rather than being an effect of the neurodegeneration. Simultaneously, these results supply a potential mechanism for the risk of E4 versus E3, the former being less able to counteract the tissue defect. The apolipoprotein E4 lipid depletion cannot itself be a consequence of Alzheimer’s disease, since cerebrospinal fluid samples were taken from individuals with no evidence of the condition. The biological gradient in ethanolamine plasmalogen deficiency mirrors the relationship of Alzheimer’s disease risk (odds ratio) to E4 allelic dose. Ethanolamine plasmalogen deficiency could be linked to, or indeed drive, several metabolic pathways implicated in Alzheimer’s pathogenesis, including amyloid-beta deposition and cholesterol dysregulation. Future studies should extend approaches to therapeutic intervention in Alzheimer’s disease which attempt to reverse this lipid abnormality.


  • Open Access

    Stroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single‐Centre Cohort

    by David Moreno‐Martinez, Sara Lucas‐Del‐Pozo, Lucia Lavalle, Uma Ramaswami, Lionel Ginsberg, Guillem Pintos‐Morell, Derralynn A. Hughes

    Objectives: Risk factors for stroke in Fabry disease (FD) are not precisely known. This study presents a retrospective cohort analysis from one reference centre in the United Kingdom to determine risk factors for stroke and to develop a predictive model. Methods: Patients > 18 years old were included in the study and were followed from their first visit until March 2019. The main outcome of the survival analysis was time to stroke. The independent risk factors were evaluated using a multivariate Cox regression. Results: Of 414 patients, 368 were included in the survival analysis. 227 (61.7%) were female, with a median baseline age of 42.7 (IQR 27.8–54.8) for males and 39.9 (26.6–51.2) years for females. 56 (39.7%) males and 64 (28.2%) females had the N215S genotype. 41 patients had a stroke at baseline (11.2%), rising to 69 (18.8%) at the end—66.7% lacunar, 18.9% anterior circulation, 13% posterior circulation and 1.4% venous thrombosis. Median follow‐up was 10.4 years. Median time to stroke in males and females was 43 (43–43) and 58 (58–59) years, respectively. In the multivariate analysis, a concomitant autoimmune disease was associated with an increased risk of stroke, while glomerular filtration rate > 90 and N215S genotype were associated with a decreased risk. Interpretation: Sex was not associated with stroke, despite males being more severe. These results might help stratify patients and are of interest not only to metabolic physicians, but to general stroke physicians too.